EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Biofilm Disruption in Methicillin-Resistant Staphylococcus aureus Using Rifampin and Fluoroquinolone Combinations

Yu Ri Kang, Joo-Young Park iD, Doo Ryeon Chung, Minhee Kang, Jae-Hoon Ko, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck iD

Pathogens · 23.04.2025 · 14 (5) · 404

DOI: 10.3390/pathogens14050404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 23.04.2025. Verfasst von Yu Ri Kang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of…. Hauptthemen laut MEDLINE: Biofilms, Rifampin, Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsung Medical Center, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Staphylococcus aureus biofilms complicate the treatment of device-related infections. We hypothesized that combining rifampin with fluoroquinolones could eradicate biofilms even in antimicrobial-resistant S. aureus strains. We determined the synergistic interactions of these combinations in a biofilm model. Thirty methicillin-resistant S. aureus (MRSA) isolates with varying susceptibility profiles were evaluated. Minimum biofilm eradication concentrations (MBECs) were determined using the Calgary Biofilm Device, and the synergy was assessed using the fractional biofilm eradication concentration (FBEC) index. Scanning electron microscopy (SEM) was performed on one strain, and confocal laser scanning microscopy (CLSM) was conducted on four strains for visualizing and evaluating the biofilm viability. The MBEC90 for rifampin and levofloxacin were 512 mg/L and 256 mg/L, respectively, and exceeded 1024 mg/L for ciprofloxacin. Synergy was observed in 56.7% of strains for both the rifampin + ciprofloxacin and rifampin + levofloxacin combinations, with no difference between the combinations. A higher ciprofloxacin MBEC (≥16 mg/L) increased the likelihood of synergy with rifampin by 18-fold. SEM and CLSM analyses in a subset of strains confirmed the enhanced biofilm disruption with rifampin + ciprofloxacin compared to ciprofloxacin alone. Our findings suggest that rifampin combined with ciprofloxacin or levofloxacin may synergistically eradicate MRSA biofilms, offering a potential treatment option for device-related infections when alternatives are limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsRifampinMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsFluoroquinolonesMicrobial Sensitivity TestsDrug SynergismLevofloxacinStaphylococcal InfectionsHumansMicroscopy, Electron, ScanningMicroscopy, ConfocalCiprofloxacin

Stichwörter der Autor:innen

confocal microscopydrug synergyfluoroquinolonesmethicillin resistancemicrobial viability

Substanzen

RifampinAnti-Bacterial AgentsFluoroquinolonesLevofloxacinCiprofloxacin

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
  • Asia Pacific Foundation for Infectious Diseases (APFID), Seoul 06367, Republic of Korea.
  • Department of Data Science, School of Software Convergence, Myongji University, Seoul 03674, Republic of Korea.
  • Biomedical Engineering Research Center, Smart Healthcare Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.

ORCID-Profile: Joo-Young Park, Kyong Ran Peck

Förderung

  • Samsung Medical Center
  • National Research Foundation of Korea

Zitieren

APA

Kang, Y. R., Park, J. Y., Chung, D. R., Kang, M., Ko, J. H., Huh, K., Cho, S. Y., Kang, C. I., & Peck, K. R. (2025). Enhanced Biofilm Disruption in Methicillin-Resistant Staphylococcus aureus Using Rifampin and Fluoroquinolone Combinations. Pathogens, 14(5), 404. https://doi.org/10.3390/pathogens14050404

Vancouver

Kang YR, Park JY, Chung DR, Kang M, Ko JH, Huh K, et al. Enhanced Biofilm Disruption in Methicillin-Resistant Staphylococcus aureus Using Rifampin and Fluoroquinolone Combinations. Pathogens. 2025;14(5):404. doi:10.3390/pathogens14050404

BibTeX
@article{Kang2025,
  author = {Kang, Yu Ri and Park, Joo-Young and Chung, Doo Ryeon and Kang, Minhee and Ko, Jae-Hoon and Huh, Kyungmin and Cho, Sun Young and Kang, Cheol-In and Peck, Kyong Ran},
  title = {Enhanced Biofilm Disruption in Methicillin-Resistant Staphylococcus aureus Using Rifampin and Fluoroquinolone Combinations},
  journal = {Pathogens},
  year = {2025},
  volume = {14},
  number = {5},
  pages = {404},
  doi = {10.3390/pathogens14050404}
}
Kostenlos starten →